JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Simulations Plus Inc

Închisă

SectorSănătate

13.81 -1.92

Rezumat

Modificarea prețului

24h

Curent

Minim

13.77

Maxim

14.18

Indicatori cheie

By Trading Economics

Venit

-70M

-67M

Vânzări

-2.1M

20M

P/E

Medie Sector

48.528

34.393

EPS

0.31

Randament dividend

0.48

Marjă de profit

-330.585

Angajați

243

EBITDA

-79M

-74M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+65.1% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.48%

2.54%

Următoarele câștiguri

22 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-90M

261M

Deschiderea anterioară

15.73

Închiderea anterioară

13.81

Sentimentul știrilor

By Acuity

55%

45%

309 / 374 Clasament în Healthcare

Simulations Plus Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 aug. 2025, 17:49 UTC

Principalele dinamici ale pieței

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug. 2025, 17:18 UTC

Principalele dinamici ale pieței

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug. 2025, 16:25 UTC

Câștiguri

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug. 2025, 16:42 UTC

Achiziții, Fuziuni, Preluări

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug. 2025, 16:27 UTC

Achiziții, Fuziuni, Preluări

BBVA Says Sabadell Offer Remains in Effect

11 aug. 2025, 16:26 UTC

Achiziții, Fuziuni, Preluări

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Announced TSB Sale on July 1

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparație

Modificare preț

Simulations Plus Inc Așteptări

Obiectiv de preț

By TipRanks

65.1% sus

Prognoză pe 12 luni

Medie 22.9 USD  65.1%

Maxim 31 USD

Minim 13.5 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSimulations Plus Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

7 ratings

4

Cumpărare

3

Păstrare

0

Vânzare

Sentiment

By Acuity

309 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.